PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26023F0144Berotralstat — Biocryst Pharmaceuticals, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Jan 19, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)
Awarding office
Biocryst Pharmaceuticals, Inc
Recipient
Jan 19, 2024
PoP end
$340K
Obligated
$340K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Biocryst Pharmaceuticals, Inc — $90

Contract facts

Federal
Contract number36C26023F0144
Also listed as36C260-23-F-0144
Also listed as36F79721D0166-36C26023F0144
Agency260-Network Contract Office 20 (36C260)
Awarding office260-Network Contract Office 20 (36C260)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentBiocryst Pharmaceuticals, Inc
CAGE4GBX7
UEIMGXADJ6SCLJ5
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79721D0166
Place of performanceROSEBURG OR
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startJan 20, 2023
PoP end (current)Jan 19, 2024
Obligated$340K
Current value$340K
Potential value$340K

BEROTRALSTAT is a federal award for 260-Network Contract Office 20 (36C260) held by Biocryst Pharmaceuticals, Inc. Estimated value $340K ($340K obligated). Current period of performance ends Jan 19, 2024. Last award drew 1 bidder. Place of performance: ROSEBURG OR.

Recompete timing

Public
Past PoP end (945 days ago)

Current PoP ended Jan 19, 2024 (945 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 36C26023F0144?

36C26023F0144 (Berotralstat) is a 260-Network Contract Office 20 (36C260) award with a potential value of $340K, currently held by Biocryst Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-23-F-0144?

36C260-23-F-0144 is the dashed form of PIID 36C26023F0144 (Berotralstat), held by Biocryst Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26023F0144?

260-Network Contract Office 20 (36C260) awarded 36C26023F0144 to Biocryst Pharmaceuticals, Inc (potential $340K).

Who is the incumbent on 36C26023F0144?

Biocryst Pharmaceuticals, Inc is the incumbent. The current period of performance ends Jan 19, 2024.

When does Biocryst Pharmaceuticals, Inc’s 36C26023F0144 come up for recompete?

SCOUT tracks a period-of-performance end of Jan 19, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C26023F0144